High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Read more about High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.
Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Read more about Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs.
Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Read more about Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions.
Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity. Read more about Pathological evidence of Wolman's disease following hematopoietic stem cell transplantation despite correction of lysosomal acid lipase activity.
Auto-SCT for AML in second remission: CALGB study 9620. Read more about Auto-SCT for AML in second remission: CALGB study 9620.
Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Read more about Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Read more about Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.
High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. Read more about High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience.
Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies. Read more about Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies.
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Read more about Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
